The global Preformulation Intermediates Market is projected to witness significant growth, expanding from an estimated USD 25.6 billion in 2025 to USD 42.1 billion by 2035, registering a CAGR of 5.1%.

While advances in drug development have accelerated dramatically in recent years, pharmaceutical manufacturing processes have struggled to keep pace – for a number of intertwined reasons. And AI ...

Galecto stock spiked on heavy trading with no clear news, while the company highlights funding plans, pipeline updates, and clinical priorities.

AI in pharmaceuticals offers key market opportunities through enhanced diagnostics, early disease detection, clinical trial optimization, drug discovery, and personalized treatments. Growth potential ...

These criteria ensure that the drug offers a genuine therapeutic difference, a requirement for its effectiveness against evolving AMR. Considering it can take 15 years and cost over $1 billion to ...

Viral diseases remain a significant challenge worldwide, compounded by the rapid emergence of drug-resistant strains. Monotherapy antivirals often struggle ...

In late September, the U.S. Food & Drug Administration (“FDA”) issued three draft guidances related to cell and gene therapy (“CGT”) products: (1) Innovative Designs for C ...

The Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics 2025 conference will gather experts to discuss trial operations amid a changing global landscape.

Apicomplexan parasites represent a diverse group of intracellular protozoans that affect both humans and animals, threatening public and animal health and ...

Nerandomilast is the first FDA-approved treatment for IPF in over a decade, targeting lung function decline. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of ...

System MarketThe global Mesenchymal Stem Cells Market is valued at USD 3.82 Billion in 2024 and is projected to reach a value of USD 9.08 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Discover Atai Life Sciences N.V.'s 275% YTD surge, driven by innovative psychedelic therapies for TRD. Click for my ATAI stock update and why I remain bullish.